BACK

Public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines

This article was published on
May 12, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

A study published in The BMJ looks at the public health impact of delaying the second dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.

A study published in The BMJ looks at the public health impact of delaying the second dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.

Publication

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

Not peer-reviewed
This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process
Peer-reviewed
This work was reviewed and scrutinised by relevant independent experts.

What our experts say

Context and background

Resources

Media briefing

Media Release

Expert Comments: 

Dr Peter English

When the phase III trial results on Covid-19 vaccines were reported, we were delighted to find that even a single dose of vaccine was far more effective than we had dared hope. It became clear that, while the bottle-neck was vaccine availability, far more lives could be saved, and hospital and critical care admissions prevented, by providing one dose to as many people as possible, particularly those at highest risk of serious Covid-19 disease outcomes, before providing second doses. This was the basis for the UK decision to delay the second dose until 12 weeks, which has proven highly effective.

This study demonstrates – using modelling – that the same is likely to apply, not just in-country, but globally; that delaying the second dose worldwide will most quickly control the disease.

There have been concerns expressed about the lack of evidence for effectiveness if the prime-boost interval is extended by delaying the second dose. These concerns are misplaced. Everything we already knew about vaccines also tells us that a longer prime-boost interval enhances the breadth and depth of the immune response, giving longer-lasting immunity that is likely to provide greater cross-protection against variant strains.

There is relatively little knowledge about this specifically related to Covid-19 vaccines – although such data as we have seen is consistent with this. It goes beyond this paper; but it seems likely that increasing the prime-boost interval will lead to better, longer-lasting immunity, as well as protecting more people more quickly.

One of the main concerns about Covid-19 is that ‘vaccine escape mutants’ (variants of the virus which are not prevented by existing vaccines) may arise. The more viral replication there is the more likely this is to happen. It is, thus, important to control the disease as far as possible globally. If we vaccinate everybody in North America and Western Europe, but vaccine escape variants arise in unvaccinated countries, they will inevitably return to the vaccinated parts of the world, causing disease there. So we all have a vested interest in ensuring that the whole world is vaccinated as soon as possible. This paper supports that view. It raises questions about, for example, the proposed third-dose (second booster) apparently planned for the UK in Autumn 2021 – it might be in the UK’s interests, as well as global interests, for those doses to be used in countries where they are needed more.

Q&A

No items found.